Journal of the Chinese Medical Association
Volume 71, Issue 7 , Pages 336-341, July 2008

Methotrexate and Leucovorin Double-modulated 5-Fluorouracil Combined with Cisplatin (MPFL) in Metastatic/Recurrent Head and Neck Cancer

  • Peter Mu-Hsin Chang

      Affiliations

    • Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
    • ,
  • Hao-Wei Teng

      Affiliations

    • Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
    • ,
  • Po-Min Chen

      Affiliations

    • Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
    • ,
  • Shyue-Yih Chang

      Affiliations

    • Department of Otolaryngology, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • ,
  • Pen-Yuan Chu

      Affiliations

    • Department of Otolaryngology, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • ,
  • Tung-Lung Tsai

      Affiliations

    • Department of Otolaryngology, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • ,
  • Shyh-Kuan Tai

      Affiliations

    • Department of Otolaryngology, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • ,
  • Yi-Fen Wang

      Affiliations

    • Department of Otolaryngology, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • ,
  • Jui-Lin Huang

      Affiliations

    • Department of Otolaryngology, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • ,
  • Muh-Hwa Yang

      Affiliations

    • Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.
    • National Yang-Ming University School of Medicine, Taipei, Taiwan, R.O.C.
    • Corresponding Author InformationCorrespondence to: Dr Muh-Hwa Yang, Division of Medical Oncology, Department of Medicine, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan, R.O.C

Received 17 December 2007; accepted 23 May 2008.

Article Outline

Background

To determine the efficacy and safety profile of the combination of cisplatin and 5-fluorouracil modulatedboth by methotrexate and leucovorin in metastatic/recurrent squamous cell carcinoma of the head and neck.

Methods

Twenty-eight patients were treated with cisplatin 40 mg/m2/day continuous infusion for 24 hours on day 1;high-dose 5-fluorouracil 2,000 mg/m2/day and leucovorin 100 mg/m2/day continuous infusion for 48 hours on days 1and 2; methotrexate 40 mg/m2/day as a bolus infusion 4 hours before 5-fluorouracil and leucovorin on day 1. The treat-ment was repeated every 2 weeks in a cycle.

Results

The overall response rate was 25%, and 14% of the patients achieved stable disease status. Subgroup analy-sis demonstrated significantly improved overall survival in the disease-control group (12.0 months vs. 5.3 months,p < 0.001). Only 3 (10.7%) patients developed grade 3–4 neutropenia, and none developed grade 3–4 non-hematologictoxicity.

Conclusion

This multiagent-containing regimen has an excellent safety profile and improved survival in disease-controlgroup of patients with metastatic/recurrent squamous cell carcinoma of the head and neck.

Key Words:  cisplatin , fluorouracil , head and neck cancer , methotrexate , mucositis

No full text is available. To read the body of this article, please view the PDF online.

 

Back to Article Outline

References 

  1. Hardisson D . Molecular pathogenesis of head and neck squamous cell carcinoma . Eur Arch Otorhinolaryngol . 2003;260:502–508
  2. Chen CL , Chi CW , Liu TY . Hydroxyl radical formation and oxidative DNA damage induced by areca quid in vivo . J Toxicol Environ Health A . 2002;65:327–336
  3. Ko YC , Huang YL , Lee CH , Chen MJ , Lin LM , Tsai CC . Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan . J Oral Pathol Med . 1995;24:450–453
  4. Lin SC, Wang CP, Chen YM, Lu SY, Fann MJ, Liu CJ, et al  Regulation of IGFBP-5 expression during tumorigenesis and differentiation of oral keratinocytes . J Pathol . 2002;198:317–325
  5. Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, et al  Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck: phase III study of the EORTC Head and Neck Cancer Cooperative Group . Ann Oncol . 1994;5:521–526
  6. Morton RP, Rugman F, Dorman EB, Stoney PJ, Wilson JA, McCormick M, et al  Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial . Cancer Chemother Pharmacol . 1985;15:283–289
  7. Colevas AD . Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck . J Clin Oncol . 2006;24:2644–2652
  8. Ardalan B, Chua L, Tian EM, Reddy R, Sridhar K, Benedetto P, et al  A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma . J Clin Oncol . 1991;9:625–630
  9. Chi KH, Chan WK, Shu CH, Law CK, Chen SY, Yen SH, et al. Elimination of dose-limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma . Cancer . 1995;76:2186–2192
  10. Delaunoit T, Marechal R, Hendlisz A, Eisendrath P, Legendre H, Pector JC, et al  Treatment of advanced digestive noncolon cancer with a weekly 24-hour infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin: an easyto-use and well-tolerated combination . Anticancer Drugs . 2004;15:725–728
  11. Hsu CH, Cheng AL, Hsu C, Yang CH, Lu YS, Lin CC, et al  A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil . Anticancer Res . 2002;22:3621–3627
  12. Hsu CH, Yeh KH, Chen LT, Liu JM, Jan CM, Lin JT, et al  Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of advanced gastric cancers: effective and low-toxicity regimen for patients with poor general condition . Oncology . 1997;54:275–280
  13. Stickel F, Jüngert B, Brueckl V, Schirner I, Brueckl WM, Männlein G, et al  Weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin . Anticancer Drugs . 2003;14:745–749
  14. Yeh KH, Cheng AL, Lin MT, Hong RL, Hsu CH, Lin JF, et al  A phase II study of weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin (HDFL) in the treatment of recurrent or metastatic colorectal cancers . Anticancer Res . 1997;17:3867–3871
  15. Bertino JR , Mini E , Fernandes DJ . Sequential methotrexate and 5-fluorouracil: mechanisms of synergy . Semin Oncol . 1983;10:2–5
  16. Caponigro F, Comella P, Marcolin P, Spena FR, Biglietto M, Carteni G, et al  A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck . Cancer . 1999;85:952–959
  17. Ringborg U , Ewert G , Kinnman J , Lundqvist PG , Strander H . Sequential methotrexate-5-fluorouracil treatment of squamous cell carcinoma of the head and neck . Cancer . 1983;52:971–973
  18. Stabuc B , Markovic A , Plesnicar A , Cizej TE . Double modulation of 5-fluorouracil by leucovorin and low-dose methotrexate in advanced colorectal cancer . Neoplasma . 2000;47:248–252
  19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada . J Natl Cancer Inst . 2000;92:205–216
  20. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, et al  Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study . J Clin Oncol . 1992;10:1245–1251
  21. Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group . J Clin Oncol . 2005;23:3562–3567
  22. Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, et al  A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck . J Clin Oncol . 1992;10:257–263
  23. Schrijvers D, Johnson J, Jiminez U, Gore M, Kosmidis P, Szpirglas H, et al  Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group . J Clin Oncol . 1998;16:1054–1059
  24. Cheng AL , Yeh KH , Lin JT , Hsu C , Liu MY . Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL): a very effective regimen with good patient compliance for advanced gastric cancer . Anticancer Res . 1998;18:1267–1272
  25. Bagrij T , Kralovanszky J , Gyergyay F , Kiss E , Peters GJ . Influence of uridine treatment in mice on the protection of gastrointestinal toxicity caused by 5-fluorouracil . Anticancer Res . 1993;13:789–793

PII: S1726-4901(08)70135-7

doi:10.1016/S1726-4901(08)70135-7

Journal of the Chinese Medical Association
Volume 71, Issue 7 , Pages 336-341, July 2008

Article Tools